The FDA recommended that REGENXBIO run a new study, treat more patients and include a placebo arm to support a resubmission ...
After facing a delayed decision deadline and a clinical hold, Regenxbio’s Hunter syndrome gene therapy has been rejected by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results